publicações selecionadas
-
artigo académico
- WNT6 is a Novel Oncogenic Prognostic Biomarker in Human Glioblastoma. Theranostics. 2018
- Ki-67 Expression in CRC Lymph Node Metastasis Does Not Predict Survival. Biomed Research International. 2015
- Frequency of TERT promoter mutations in human cancers. Nature Communications. 2013
- Increased hepatic expression of TLR2 and TLR4 in the hepatic inflammation-fibrosis-carcinoma sequence. Innate Immunity. 2012
- Impact of EGFR genetic variants on glioma risk and patient outcome. Cancer Epidemiology Biomarkers & Prevention. 2011
- Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: A Portuguese multicentre study. Oncology Reports. 2010
- TP53 codon 72 polymorphism in susceptibility, overall survival, and adjuvant therapy response of gliomas. Cancer Genetics and Cytogenetics. 2008
- Association between functional EGF+61 polymorphism and glioma risk. Clinical Cancer Research. 2007
- Mutation analysis of B-RAF gene in human gliomas. Acta Neuropathologica. 2005
-
documento
- Functional and prognostic relevance of CDH3/P-cadherin in glioblastoma 2019
- CDH3/P-cadherin is an oncogenic biomarker in glioblastoma 2019
- CDH3/P-cadherin expression is associated with aggressiveness of human glioblastoma 2018
- CDH3/P-cadherin as a novel biomarker in glioblastoma: functional and prognostic insights 2018
- Functional impact and prognostic relevance of CDH3/P-cadherin in glioblastoma 2018
- CDH3/P-cadherin as a putative HOXA9 target in gliomas: functional and clinical relevance 2017
- Regulation of WNT6 by HOXA9 in glioblastoma: functional and clinical relevance 2016
- Analysis of EGFR Overexpression, EGFR gene amplification and the EGFRvIII Mutation in portuguese high-grade gliomas. Anticancer Research. 2008
- Molecular alterations of KIT oncogene in gliomas. Cellular Oncology. 2007
- Analysis of TP53 mutations in Diffuse Astrocytomas. 2006